PROSPECTIVE STUDY OF SAFETY AND EFFICACY OF INTRAVENOUS FERRIC CARBOXY MALTOSE IN IRON DEFICIENCY ANAEMIA IN WOMEN ATTENDING GYNAECOLOGICAL CLINIC.

Abstract

Abstract

BACKGROUND: Iron deficiency anaemia is the common nutritional deficiency amongst women of child bearing, perimenopausal and postmenopausal age in both the developed and developing countries and is a leading cause of Anaemia. There are various intravenous iron preparations available for the treatment of IDA. Ferric carboxymaltose (FCM), a nondextran intravenous iron, is an effective and a safe option which can be administered in high single doses directly over 7-8 minutes or diluted in saline for infusion without serious adverse effects.

METHODS: Total dose of ferric carboxy maltose (FCM) was calculated on the basis of Haemoglobin deficit and body weight using GANZONI FORMULA. FCM is administered as an infusion diluted in sterile 0.9% NaCL solution. The drug was administered under direct supervision and infusion was immediately stopped in case of any side effects. The patient should be followed up after 3 weeks of total dose infusion to assess the status of iron stores and increase in haemoglobin.

RESULTS: Mean age of the participants was 25.34 ± 5.09 years in which 42% of the subjects were primiparous and 58% were multiparous. Among them 96% were having pallor. 2% of the subjects had a pre iron Hb of <7, 98% had Hb between 7.1-9 and the mean pre iron Hb was 7.76 ± 0.48. Post Iron Hb, 12% had Hb between 7.1-9, 88% had Hb of 9.1-11 and the mean post iron HB was 9.40 ± 0.66.  In the present study a statistically significant difference was observed between the mean Pre-Iron and Post Iron Hb levels

CONCLUSION: Due to properties like ultra-short duration of treatment i.e. ability to administer 1000 mg doses in a single sitting, fewer adverse reactions and better compliance makes FCM the first-line drug in the management of iron deficiency anemia in postpartum, perimenopausal and postmenopausal women causing a faster and higher replenishment of iron stores and correction of Hb levels. Also use of high doses reduces the number of infusions, enabling the possibility of cost reductions compared to multiple administrations